ER Positive Breast Cancer
16
8
10
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
6.3%
1 terminated out of 16 trials
66.7%
-19.8% vs benchmark
13%
2 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (16)
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Supporting Health Including Endocrine Treatment for Long Duration
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Role of the Immune Environment in Response to Therapy in Breast Cancer
PRE-I-SPY Phase I/Ib Oncology Platform Program
To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer
D4 Choline Breast PET/CT
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
Fulvestrant + Neratinib In Breast Cancer
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer